There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TGF-beta RII

TGF-beta RII

Brief Information

Name:Transforming growth factor beta receptor 2
Target Synonym:EC:,NONHSAG034676,Transforming growth factor-beta receptor type II,TbetaR-II,TGF-beta type II receptor,TGFBR2,Transforming Growth Factor, Beta Receptor II (70/80kDa),Transforming Growth Factor Beta Receptor II,TGFR-2,Transforming Growth Factor, B
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

Human TGF-beta RII, His TagHuman TGF-beta RII, His Tag (Cat. No. TG2-H52H5) ELISA bioactivity

Serial dilutions of Human TGF-beta RII, His Tag (Cat. No. TG2-H52H5) were added into Human Latent TGFB1, His Tag (Cat. No. TG1-H524x) : Biotinylated Human TGF-beta RII, His,Avitag (Cat. No. TG2-H82E4) binding reactions. The half maximal inhibitory concentration (IC50) is 0.39287 μg/mL (QC tested).

Biotinylated Human TGFBR2, Fc,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human TGFBR2, Fc,Avitag (Cat. No. TG2-H82F6) was more than 90% and the molecular weight of this protein is around 110-125 kDa verified by SEC-MALS.

Biotinylated Human TGFBR2, Fc,AvitagBiotinylated Human TGFBR2, Fc,Avitag (Cat. No. TG2-H82F6) ELISA bioactivity

Immobilized Human Latent TGFB1, His Tag (Cat. No. TG1-H524x) at 2 μg/mL (100 μL/well) can bind Biotinylated Human TGFBR2, Fc,Avitag (Cat. No. TG2-H82F6) with a linear range of 2-16 ng/mL (QC tested).

Synonym Name



TGF-beta receptor type-2 (TGFBR2 or TGFR-2) is also known as TGF-beta type II receptor, Transforming growth factor-beta receptor type II, TbetaR-II, TGFβR2, which is a homodimer or heterohexamer, belongs to the protein kinase superfamily, TKL Ser/Thr protein kinase family and TGFB receptor subfamily. TGFR2 / TGFBR2 binds TGF-β1 / TGFB1 and TGF-β3 / TGFB3 with high affinity and TGF-β2 / TGFB2 with a much lower affinity. This type I I receptor forms a heterodimeric complex with type I  receptor and is essential for signal transduction. Upon ligand binding, the TGFR2 autophosphorylates its cytoplasmic domain and subsequently phosphorylates the downstream molecules which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Netarsudil Dimesylate AR-13224; AR-13324 Approved Aerie Pharmaceuticals Rhopressa EU Ocular Hypertension; Glaucoma, Open-Angle Aerie Pharmaceuticals Ireland Ltd 2017-12-18 Glaucoma, Open-Angle; Ocular Hypertension; Glaucoma; Corneal Edema; Fuchs' Endothelial Dystrophy Details
Netarsudil mesylate/Latanoprost PG-324 Approved Aerie Pharmaceuticals Inc Rocklatan, Roclanda EU Glaucoma, Open-Angle; Ocular Hypertension Aerie Pharmaceuticals Ireland Ltd 2019-03-12 Glaucoma, Open-Angle; Ocular Hypertension Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Adoptive Cell Therapy (Oslo University Hospital) Phase 2 Clinical Oslo University Hospital Colorectal Neoplasms Details
Trabedersen OT-101; OT-201; AP-2/09; AP-12009; AP-2/09-DS Phase 3 Clinical Isarna Therapeutics Coronavirus Disease 2019 (COVID-19); Glioblastoma; Pancreatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Melanoma Details
TASO-001 TASO-001; ATB-301 Phase 1 Clinical Solid tumours Details

This web search service is supported by Google Inc.